Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB
Department of Oncology, Radiology and Clinical ImmunologyUppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Genetics and PathologyInterfaculty Units, Centrum för klinisk forskning, Gävleborg2003 (English)In: European Journal of Haematology, ISSN 0902-4441, Vol. 71, no 5, 327-33 p.Article in journal (Refereed) Published
The aim of this study was to evaluate treatment results for Hodgkin lymphoma (HL) patients younger than 60 yr in stage IIB, treated according to the Swedish National Care Programme. The intention was also to identify specific subgroups depending on the number of negative prognostic factors the patients have, in order to optimise and differentiate future treatment. In total, 99 patients with HL stage IIB, diagnosed between 1985 and 1994, have been analysed. There were 47 men and 52 women and the median age was 33 yr (range 17-59). Eighty-six patients presented with supradiaphragmatic disease and 13 with infradiaphragmatic. The HL specific and overall 10-yr survival was 73 and 65%, respectively. The HL-specific survival for patients in pathological stage IIB tended to be better, although not statistically significant than for clinical stage IIB, despite less chemotherapy (P = 0.1). The patients in stage IIB who were selected for laparotomy were, however, younger and with fewer negative prognostic factors. The only significant negative prognostic factor was bulky disease (P = 0.001). The following factors also tended to have a negative influence on the prognosis although not statistically significant: the International Prognostic Score, the number of involved lymph node stations, extranodal involvement and leucocyte count > 15 x 10(9)/L. In conclusion, we suggest that bulky disease should be taken into account when treating patients with stage IIB HL.
Place, publisher, year, edition, pages
2003. Vol. 71, no 5, 327-33 p.
Hodgkin lymphoma, stage IIB, bulky disease
Medical and Health Sciences
Research subject Oncology
IdentifiersURN: urn:nbn:se:uu:diva-71726DOI: 10.1034/j.1600-0609.2003.00108.xPubMedID: 14667195OAI: oai:DiVA.org:uu-71726DiVA: diva2:99637